Company Description
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.
Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis.
The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.
Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
| Country | Canada |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | James Helliwell |
Contact Details
Address: 2067 Cadboro Bay Road, Suite 201 Victoria, BC V8R 5G4 Canada | |
| Phone | 250 590 3968 |
| Website | eupraxiapharma.com |
Stock Details
| Ticker Symbol | EPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1581178 |
| ISIN Number | CA29842P1053 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James A. Helliwell FRCPC, M.D. | Chief Executive Officer and Director |
| Dr. Amanda Malone Ph.D. | Chief Scientific Officer and Chief Operating Officer |
| Paul Anthony Brennan B.Sc., M.Sc. | Chief Corporate Development Officer |
| Alexander John Rothwell Eng., M.B.A. | Chief Financial Officer |
| Alex Therien | Executive Vice President of Research & Development |
| Dr. Jeymi Tambiah M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 6-K | Report of foreign issuer |
| May 6, 2026 | 6-K | Report of foreign issuer |
| May 5, 2026 | 6-K | Report of foreign issuer |
| May 1, 2026 | 6-K | Report of foreign issuer |
| Apr 22, 2026 | 6-K | Report of foreign issuer |
| Apr 21, 2026 | 6-K | Report of foreign issuer |
| Apr 15, 2026 | 6-K | Report of foreign issuer |
| Apr 15, 2026 | 6-K | Report of foreign issuer |
| Mar 17, 2026 | 6-K | Report of foreign issuer |